Laboratoires Servier

Servier Laboratories (French: Laboratoires Servier, often abbreviated to Servier) is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes).[3]

This article is about the pharmaceutical company. For other uses, see Servier (disambiguation).
Servier
TypePrivate
IndustryPharmaceutical
Founded(1954 (1954))
FounderJacques Servier
Headquarters
Suresnes
,
France
ProductsPharmaceuticals
Revenue€4.2 billion (FY 2018)
Number of employees
22,000
WebsiteOfficial website
Footnotes / references
[1][2]

The consolidated turnover for the 2018 financial year was €4.2 billion.[4] Servier is the leading French independent pharmaceutical company, and the second largest French pharmaceutical company worldwide. It has branches in 149 countries, achieving 82% of its sales outside France.[5][6] The company reportedly invests a little under 25% of its turnover in research and development, which occupies 3,000 of its 22,000 employees worldwide.[7] The company's production sites produced 853 million drug boxes in 2013.[5]

The Servier Clinical Support Unit in Gidy (near Orléans), which produces drugs for clinical trials, is the largest unit of its kind in Europe.[8] Servier Laboratories is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).[9]

In 2018, Servier finalized the acquisition of Shire’s oncology branch in Boston. The official opening of Servier's new U.S. headquarters took place in 2019.[4]

In 2009, Mediator, an amphetamine-based Servier drug originally developed for weight loss in people with diabetes but often prescribed off-label as a dieting aid, was withdrawn from the market after being linked to 500–2000 deaths in France.[10][11] Further investigations found that many previous safety alerts on that drug had been either missed or covered up, possibly due to the improper influence of the company.[11]

Product portfolio

Notable products:

Other products:

Collaborative research

As well as internal research and development activities, Servier undertakes publicly funded collaborative research projects with industrial and academic partners. One example, in the area of non-clinical safety assessment, is the InnoMed PredTox.[14][15] The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.[16]

In addition to these, Servier engages in research and licensing collaborations across the pharmaceutical and biotechnology industry. These collaborations include:

  • In Cardiology: XENTION (UK, 2013), AMGEN (USA, 2013), MIRAGEN (USA, 2011), ARMGO (USA, 2006)
  • In Diabetes: INTARCIA (USA, 2014)
  • In Metabolic diseases: INTERCEPT - TGR5 agonists (USA, 2011), GENFIT (FR, 2004)
  • In Neurology (MS): GENEURO (CH, 2014)
  • In Oncology: CTI BIOPHARMA (USA, 2014), NOVARTIS (CH, 2014), CELLECTIS (FR, 2014), NERVIANO (IT, 2013), EOS (IT) / CLOVIS (USA, 2012), BIOINVENT (SE, 2012), MACROGENICS (USA, 2011/12), GALAPAGOS (NDL, 2011), BIOREALITES (FR, 2011), PHARMACYCLICS - HDAC inhibitor (USA, 2009), HYBRIGENICS (FR, 2007/2011) VERNALIS (UK, 2007/2011)
  • In Orphan Diseases/Cardiology/Diabetes: XOMA (USA, 2010)
  • In Osteoporosis & Osteoarthritis: OSTEOLOGIX (USA, 2010), GALAPAGOS (NDL, 2010), KAROS (USA, 2010), NORDIC BIOSCIENCE (DK, 2006/2010)

Servier acquired Symphogen in 2020.[17]

Controversy

Servier Laboratories has been the object of worldwide scandal for creating and distributing a weight-loss drug called Mediator, which may have killed up to 2,100 people.[18]

The movie 150 Milligrams, by director Emmanuelle Bercot, features Dr. Irène Frachon discovering that Mediator pills cause heart valve problems/deaths and how in 2009 she starts an uphill battle against the producer and the French health authorities.

References
  1. "Key figures". Servier. Retrieved 2015-02-03.
  2. "History". Servier. Retrieved 2015-02-03.
  3. "French drug maker Servier sets up US headquarters in Seaport". Boston Globe. May 9, 2019.
  4. "Servier launches U.S. cancer business with plans to double headcount in next 5 years". Boston Business Journal. May 9, 2019.
  5. "SERVIER - Pharmaceutical company specialized in cardiology, diabetes, rheumatology, depression". Retrieved 2007-07-08.
  6. "Servier and Galapagos complete enrollment of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis". Bloomberg. June 11, 2019.
  7. "Servier's US push takes shape as Boston HQ opens". BioPharma Dive. May 9, 2019.
  8. "Servier UK - Key figures". Archived from the original on 2007-07-08. Retrieved 2007-07-08.
  9. "The Pharmaceutical Industry in Figures - 2008 Edition". European Federation of Pharmaceutical Industries and Associations (EFPIA). p. 49. Archived from the original on 2008-09-16. Retrieved 2008-08-25.
  10. Article of the Figaro about Mediator
  11. Un doute sur la «sécurité» du Mediator dès 1998 - Libération
  12. "SERVIER - product portfolio". Archived from the original on 2007-07-02. Retrieved 2007-07-08.
  13. https://servier.com/wp-content/uploads/2018/08/PR-Servier-Shire-Oncology-Acquisition_2018.08.31.pdf
  14. Mattes, William B. (2008). "Public Consortium Efforts in Toxicogenomics". In Mendrick, Donna L.; Mattes, William B. (eds.). Essential Concepts in Toxicogenomics. Methods in Molecular Biology. 460. pp. 221–238. doi:10.1007/978-1-60327-048-9_11. ISBN 978-1-58829-638-2. PMID 18449490.
  15. "InnoMed PredTox Member Organizations". Archived from the original on 2008-09-26. Retrieved 2008-08-25.
  16. Innovative Medicines Initiative. "IMI Call Topics 2008". IMI-GB-018v2-24042008-CallTopics.pdf. European Commission. Archived from the original on 2009-10-15. Retrieved 2008-08-25.
  17. A/S, Symphogen (3 April 2020). "Servier signed a definitive agreement to acquire Symphogen, a leading antibody discovery company, to boost its antibody capabilities and leverage its R&D pipeline". GlobeNewswire News Room.
  18. Samuel, Henry (2019-09-23). "Trial opens in France over weight loss drug that 'killed hundreds'". The Telegraph. ISSN 0307-1235. Retrieved 2020-04-03.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.